Brief: Inovio Plans To Submit BLA For Ino-3107 In H2 2024 Under Accelerated Approval Program
03/01/2024 13:12
Jan 3 (Reuters) - Inovio Pharmaceuticals Inc INO.O :
* INOVIO PLANS TO SUBMIT A BLA FOR INO-3107 AS A POTENTIAL
TREATMENT FOR RRP IN SECOND HALF OF 2024 UNDER ACCELERATED
APPROVAL PROGRAM
* WILL REQUEST ROLLING SUBMISSION & PRIORITY REVIEW OF
BIOLOGICAL
LICENSE APPLICATION BY U.S FDA TO EXPEDITE REVIEW PROCESS
* ACCELERATING COMMERCIALIZATION EFFORTS TO BE PREPARED TO
LAUNCH
INO-3107 IN 2025
Source text for Eikon: ID:nPn8xcXSCa
Further company coverage: INO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inovio Pharmaceuticals
See all newsBrief: Inovio Announces Favorable Judgment In Litigation With Vgxi, Inc. And Geneone Life Science
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Inovio Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Inovio Q2 net loss narrows on warrant gain, lower costs
Brief: Inovio Pharmaceuticals Q2 Operating Expenses USD 18.6 Million